Company Cash Funds: Halozyme (HALO)

Official company branding of Halozyme Corp (HALO)

ENHANZE patents and stringent FDA oversight create an insurmountable barrier for competitors. Stable royalties render the business insensitive to market volatility. The cash trajectory clearly demonstrates liquidity, where the value of 1.07 captures the metric level. Halozyme Therapeutics (HALO) growth relies on the success of clinical trials and the rollout of innovations, ensuring independence from economic cycles.

HALO - Halozyme Corp Company Cash Reserve over the range 07/04/2022 - 11/21/2026

Comprehensive metric breakdowns and analytics for Halozyme (HALO)

- company stock exchange capitalization indicators:
Fundamental valuation:Halozyme Therapeutics, Inc.
Product sample of halozyme.com

Halozyme Therapeutics (HALO) utilizes a high-margin licensing model for its ENHANZE technology, minimizing capital expenditures. This indicator captures the absolute volume of liquid assets, allowing for the tracking of real capital accumulation trends. By analyzing operating cash flow, an investor assesses the business's ability to accumulate resources without commercialization risk. The steady growth of this metric confirms the exceptional resilience of the asset-light structure and the predictability of cash flows.

Competitors of Halozyme Therapeutics (HALO)

Company Cash Volume ONC|Company Cash Volume Revolution Medicines, Inc. (RVMD)|Company Cash Volume AAPG (ascentage.com)|CG Oncology Inc (CGON) - Company Cash Reserve|URGN - Company Cash Funds|Bicara Bio - Company Total Cash Amount|PSNL: Company Cash Volume|Company Cash and Cash Equivalents ERAS|Company Cash on Hand DCTH|Company Cash Reserve Y-mAbs Therapeutics Inc YMAB|Company Cash Volume AURA|CADL (Candel Therapeutics, Inc.) - Company Cash Balance|Company Cash Funds Accuray Inc ARAY|Company Liquid Assets SELLAS Life Sciences Group Inc. (SLS)|actuatetherapeutics.com - Company Cash Volume|Company Cash Reserve Citius Oncology|HURA: Company Cash Volume|Company Total Cash Volume TARA (Protara)|FATE (fatetherapeutics.com) - Company Cash Volume|Company Cash Reserve Aadi Bioscience WHWK|Company Cash Volume TCRX|CSBR - Company Cash Reserve|XBiotech - Company Cash on Hand|CEL-SCI Corporation (CVM) - Company Cash Reserve|OSTX - Company Cash Funds|Company Cash Reserve Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Company Cash on Hand|ANL (Adlai Nortye Ltd) - Company Cash Funds|Company Cash on Hand VERU|Tempest Therapeutics (TPST) - Company Liquid Assets|Company Cash Volume XLO|Company Cash on Hand Renovaro RENB|Company Cash Volume MURA (Mural Oncology PLC)|KAPA - Company Cash on Hand|OnKure Therapeutics - Company Cash Volume|w2.cytomed.sg - Company Total Cash Amount|Curis Corp (CRIS) - Company Cash Funds|Company Cash Reserve Apollomics Corp (APLM)|Company Cash Funds Tharimmune|Company Cash Volume advanbiomed.com|Company Cash Funds Genprex, Inc (GNPX)|Company Liquid Assets Calidi Biotherapeutics, Inc.|Company Cash Volume SBFM (Sunshine Biopharma Inc.)|XBIO - Company Cash on Hand|SLRX: Company Cash on Hand|Company Cash Balance PPBT (Purple Biotech Ltd.)|AONC: Company Cash Volume|Company Cash Reserve BeOne Medicines (BGNE)|Company Cash Funds Checkpoint Therapeutics, Inc.|Company Cash on Hand Elevation Oncology (ELEV)|Company Cash Funds iCAD Corp (ICAD)|Company Cash on Hand Ikena IKNA|Company Cash Volume NTBL (notablelabs.com)|VIRX - Company Cash on Hand|MOR: Company Cash on Hand|NAYA - Company Cash Volume|Ascentage Pharma (AAPGV) - Company Cash Funds